Video wird geladen...

Video konnte nicht geladen werden

Zur Startseite

Priv Journal: Week 1 consideration prior to expansion. Initial Target 99.544 Hit (SMT) = proceed & partial with caution everything else now becomes not guranteed

10,869 Aufrufe • vor 1 Monat •via X (Twitter)

0 Kommentare

Keine Kommentare verfügbar

Kommentare vom Original-Post werden hier angezeigt

Ähnliche Videos

📺 $TSLA HIT THE TARGET — TIME TO TAKE PROFITS? Please ❤️like and 🔁share with fellow Tesla traders/investors #Tesla closed Monday at $445.00, already reaching and slightly exceeding the key upside target of $442.26, which we had been anticipating for several weeks after bouncing from $347.63 long-term support. Price is now sitting right at a critical resistance zone: $442.26 → prior target, $444.99 → 5-week rising channel top. So, the key question now – is $TSLA just stretching into resistance (likely a pause/pullback)? Or has it broken through resistance (start of a new leg higher)? We are leaning toward “stretching” for now, not a confirmed breakout yet. For a true continuation higher, price behavior matters. We need a close above $444.99 (ideally two consecutive closes above this level). If this happens, the momentum “pull-away” effect kicks in, and short-term upside targets become: – $453.29 → next resistance (descending channel top) – $474.07 → major target (Nov high zone) If strength builds, $474.07 reachable mid this week (Wed–Thu). If #TSLA closes this week above $444.99, $498.83 (Dec high) is likely within 3–5 weeks, and $541.33 is possible within 2–3 months. This becomes a strong trend-continuation phase. * Today, if $TSLA opens above $444.99 → a quick move to $453.29 is possible. If it breaks above $453.29 → $474.07 becomes reachable even intraday. * Warning signals: – Failure to hold above $444.99 – Close back below $442.26 Stronger downside trigger: – Close below $415.83 → signals trend breakdown $387.07 becomes the downside target. This would shift the structure from trend continuation to a corrective pullback. * So, if already long, stay long, but watch key levels closely. If unsure, wait for a confirmation (close above $444.99). If you are not in yet, your entry becomes more attractive after a confirmed breakout, targeting the $500–$540 range. * So, $TSLA has completed its initial upside move and is now at a critical resistance zone. The market is deciding between: – Pause/consolidation (most likely near-term) – Aggressive breakout into a new bullish phase (if resistance breaks) Everything hinges on how the price behaves around $444.99 this week. * Watch the full Trading Plan for May 12, 2026 in this short video🔽

Wicked Stocks

20,630 Aufrufe • vor 2 Monaten

Today we’re reporting interim Phase 1 clinical data for our REC-617 monotherapy trial – with plans to expand into combination studies in advanced solid tumors. At the AACR Special Conference in Cancer Research, CSO David Hallett shared interim monotherapy dose-escalation data from the Phase 1/2 study (ELUCIDATE) of REC-617, a selective CDK7 inhibitor, in advanced solid tumors. 🔹The interim Phase 1 clinical data for REC-617 included: ▫️Dose-linear pharmacokinetics (PK) with rapid absorption and robust pharmacodynamic (PD) biomarker modulation, suggesting substantial target engagement; ▫️Confirmed partial response (PR) during monotherapy dose-escalation in a patient with platinum-resistant ovarian cancer, treated with 4 lines of prior therapy in an advanced setting, with durable response ongoing after more than 6 months of treatment; ▫️In 4 additional patients, a best response of stable disease (SD) for up to 6 months of treatment. Dr. Hallett noted: “Cell cycle dysregulation and transcriptional 'addiction' are both hallmarks of many aggressive cancers. By inhibiting CDK7, we have the potential to target both mechanisms while fine tuning the therapeutic index.” "These initial findings for REC-617 represent an exciting step forward in the development of CDK7 inhibitors, with a favorable PK/PD profile and a durable confirmed partial response observed in dose escalation in a highly pre-treated patient population," said Najat Khan, Ph.D., Chief R&D Officer and Chief Commercial Officer. “Designed using our AI-powered OS platform, REC-617 reflects our focus on enhancing the therapeutic index to deliver more effective and safer treatment options for patients. We are eager to continue this momentum in dose escalation and to initiate the next phase of the program next year." 👉Learn more: 🔹Join the Update Call: Tomorrow, Tues., Dec. 10 at 8:30am ET, Dr. Hallett and Dr. Khan will hold a live Update Call webcast to present the preliminary data. ▫️Submit questions for the Update Call here: ▫️Tune in to the Update Call here on X or on: LinkedIn: YouTube:

Recursion

11,879 Aufrufe • vor 1 Jahr

Elon Musk just revealed what happens when Neuralink and Optimus merge, and it’s not about helping the disabled. It’s about making them better than you. “You’d have basically Cybernetics Superpowers.” Not recovery. Evolution. Lose a limb and the replacement isn’t restoration. It’s upgrade to capabilities biology never provided. Optimus hardware. Neuralink bandwidth. Brain commands routing directly to mechanical limbs with zero latency. Musk: “The motor commands from your brain… now go to your robot arms or robot legs.” Neural signals hit robotic targets. Thought becomes motion. Precision exceeding anything flesh achieved. Not fixing disability. Creating advantage. Musk: “Combine that with a Neuralink.” Where his two biggest projects collide. Medical application for amputees becomes the wedge. Optimus arm attached. Neuralink implanted. Brain signals reroute to mechanical hardware seamlessly. Think movement. Machine executes. Not approximation of biological function. Direct neural control of superior platform. Musk: “Motor commands from your brain… go to your robot arms.” The gap between human and machine is just wiring. Neuralink bridges it. Optimus provides hardware that outperforms biology in every metric. Robotic limb lifts ten times more. Reacts faster. Never tires. Never weakens. The replacement isn’t equivalent. It’s superior. Musk: “And again, you’d have basically Cybernetics Superpowers.” We’re not restoring function. We’re demonstrating that biology was the limitation. Once someone with Optimus limbs provably outperforms biological humans, injury stops being tragedy and becomes competitive edge. The amputee isn’t disadvantaged anymore. They’re enhanced. Stronger. Faster. More capable than intact humans beside them. That’s when everything inverts. Disability stops being disability when the replacement exceeds the original. And once performance gap becomes visible and measurable, keeping biological limbs becomes the handicap. Why biological arm strength when mechanical replacement lifts exponentially more? Why biological endurance when robotic systems don’t fatigue? Why accept limitations when alternatives eliminate them? The injured person with upgrades isn’t trying to reach normal. They surpassed it. And everyone still constrained by biology just became comparatively disabled. At that point, waiting for injury to get enhancement becomes irrational. People seek elective replacement. Functional biology gets swapped for superior mechanics because performance matters more than origin. Your body isn’t sacred. It’s legacy hardware running obsolete specifications. And when better hardware integrates seamlessly through neural interface, keeping the original stops being preservation and becomes self-imposed limitation. Neuralink plus Optimus doesn’t help the disabled catch up to the able-bodied. It makes the able-bodied obsolete. And once that’s obvious, once enhanced humans demonstrably outcompete biological ones, the question stops being whether we should upgrade and becomes how fast we can before everyone else does and we’re left behind operating with inferior equipment. The disabled aren’t getting fixed. They’re getting first access to the platform that makes everyone else obsolete. And biology’s reign as optimal human configuration just got an expiration date.

Dustin

76,633 Aufrufe • vor 5 Monaten

Elon Musk pours hundreds of millions into buildings the government can force him to demolish. On purpose. Musk: “One of the approaches we did take was to proceed at risk with temporary permits.” Not approved. Not guaranteed. Temporary. He builds knowing the exact consequences. Musk: “Your long-term permit could be denied, in which case you have to stop everything.” Everything. Every wall. Every foundation. Back to dirt. Musk: “Most companies are not willing to take the risk of the temporary permit, and then the risk of having to stop and tear down.” That single sentence explains why the West forgot how to build. The system never needed to reject you. It just needed you to believe waiting was the responsible thing to do. Delays stack. Capital bleeds. Teams scatter. Conviction rots. The project dies quietly in a conference room on a Tuesday afternoon. Nobody writes about it. That was the point. The regulatory machine doesn’t build walls. It builds fog. Thick enough that most people turn around before they ever hit anything solid. You were never told no. You were told “not yet” until you forgot why you started. Musk doesn’t negotiate with “not yet.” He pours concrete while the paperwork is still moving. If they deny it, he tears it all down and starts again. Because he understands something the modern world was trained to forget. The cost of demolition is a number. The cost of standing still is everything you will never build. One of those kills a project. The other kills a civilization. Everyone else got that math backwards. And they were taught to call it responsible.

Dustin

105,041 Aufrufe • vor 11 Tagen